Shares in CSL Ltd (ASX:CSL) surged 16.02% to A$156.16 by 11:01am on Tuesday, adding A$21.56, as investors reacted positively to the healthcare giant’s FY26 results and, more importantly, its plans to return to sustainable growth.

The sharp rally comes despite CSL reporting a US$2.6 billion statutory net loss for FY26, with the market instead focusing on the company’s underlying earnings, strong cash generation, cost-cutting progress, resilient plasma Business and a fresh A$1.1 billion share buy-back.

Why is the CSL share price jumping?

The headline statutory loss looks ugly, but it was heavily distorted by billions of dollars of restructuring costs and asset impairments.

CSL reported:

  • US$15.8 billion in total revenue, down 1%
  • US$3.1 billion in underlying NPATA, down 2%
  • US$2.6 billion net loss after tax, compared with a profit in FY25
  • US$3.5 billion in operating cash flow
  • US$176 million of cost savings achieved through its transformation program
  • 1.8x leverage, leaving the Balance Sheet in a relatively strong position

The key takeaway for investors is that the enormous statutory loss does not represent the underlying performance of CSL's operating businesses.

The company recognised US$7.1 billion of pre-tax impairments during FY26, alongside US$799 million of pre-tax restructuring costs. These charges were linked to changes in commercial outlook, generic competition, regulatory developments, market conditions and site utilisation.

That has allowed the market to look beyond the headline loss and concentrate on what CSL's Earnings could look like after the restructuring.

A fresh A$1.1 billion buy-back is a major positive

One of the biggest catalysts for the share price is CSL's decision to launch another A$1.1 billion share buy-back.

The company says its strong cash flow and balance sheet have given it the capacity to return additional Capital to shareholders while continuing to invest in the business.

CSL also maintained its dividend, with a final Dividend of US$1.62 per share, expected to be approximately A$2.29 for Australian shareholders at the relevant exchange rate.

The combination of a maintained dividend and substantial buy-back provides an immediate shareholder-return component to the Investment case.

FY27 guidance points to a recovery

Perhaps the most important part of today's announcement is CSL's FY27 outlook.

The company expects:

  • Revenue to be broadly in line with FY26
  • Underlying NPAT growth of approximately 5%
  • CSL Behring Revenue growth in the mid-single digits
  • Immunoglobulin growth in the mid-to-high single digits
  • CSL Seqirus revenue growth of low single digits
  • CSL Vifor revenue to fall approximately 25%

That outlook suggests management believes FY26 represented a trough or reset year rather than the beginning of a prolonged earnings decline.

CSL described FY26 as a "year of reset", with the transformation program now moving into a phase where the benefits should increasingly flow through to earnings.

The plasma business remains the foundation

CSL Behring remains the group's largest business, generating US$11.4 billion of revenue in FY26.

While revenue declined 1%, the underlying fundamentals of the plasma industry remain supportive.

Immunoglobulin sales were approximately US$6.2 billion, broadly flat, despite several temporary headwinds including US channel inventory normalisation, Medicare Part D changes and tender losses.

CSL is also investing around US$1.5 billion to expand its US plasma Manufacturing footprint and improve yields through its Horizon 2 program.

The company says plasma market fundamentals and Demand remain robust, while newer products such as ANDEMBRY and HEMGENIX are building momentum.

ANDEMBRY generated US$240 million in its first full year on the market, while HEMGENIX sales increased 25%.

Cost savings could provide another earnings lever

CSL has made substantial progress simplifying its operations.

The company achieved approximately US$176 million in cost savings during FY26, ahead of its original target.

The restructuring has reduced fixed infrastructure and eliminated duplication following the integration of Behring and Vifor commercial and medical affairs.

CSL also expects the restructuring of its APAC metals manufacturing operations to deliver approximately US$9 million in net annual cost reductions from FY28.

This is important because CSL's FY26 adjusted EBITDA Margin fell to 18.5%, from 21.1% a year earlier.

The investment case therefore isn't simply dependent on revenue growth. Investors are also looking for margin recovery as cost savings, manufacturing improvements and the company's transformation program begin to take effect.

There are still plenty of risks

The rally doesn't mean CSL has suddenly become a low-risk growth stock.

The company continues to face significant challenges, including:

  • US healthcare and reimbursement changes
  • Generic competition
  • Pricing pressure
  • Lower US immunisation rates
  • Regulatory risks
  • Manufacturing and plasma collection risks
  • Foreign exchange movements
  • Weak economic conditions across some major markets

CSL Vifor is particularly challenging, with FY27 revenue expected to fall around 25% because of generic competition in iron products, the end of the TDAPA period for VELPHORO and the revocation of TAVNEOS' Marketing authorisation.

Meanwhile, CSL Seqirus is expecting only low-single-digit revenue growth.

The market is looking through the FY26 loss

Today's share-price reaction therefore appears to be less about the FY26 numbers themselves and more about what comes next.

CSL has effectively taken a large number of difficult decisions in FY26: recognising substantial impairments, restructuring parts of the business, cutting costs, simplifying operations and investing in its core plasma manufacturing capabilities.

At the same time, it has maintained its dividend and announced another A$1.1 billion buy-back.

With management forecasting around 5% underlying NPAT growth in FY27, investors appear to be betting that the worst of the earnings reset is behind the company.

The bottom line

CSL's 16% share-price surge is essentially a vote of confidence in the company's post-reset earnings potential.

The headline US$2.6 billion loss is being largely discounted because it was driven by enormous non-recurring impairments and restructuring charges. Instead, investors are focusing on the company's US$3.1 billion underlying NPATA, US$3.5 billion operating cash flow, cost savings, strong balance sheet, maintained dividend and A$1.1 billion buy-back.

The crucial test from here will be whether CSL can translate its restructuring and investment program into the ~5% underlying NPAT growth forecast for FY27, while returning its core Behring business to sustainable growth.